EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 41 / Numéro 11 (Novembre 2025) Med Sci (Paris), 41 11 (2025) 888-899 Références
Numéro
Med Sci (Paris)
Volume 41, Numéro 11, Novembre 2025
L’antibiorésistance au prisme des trois santés
Page(s) 888 - 899
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2025193
Publié en ligne 12 décembre 2025
  1. Waksman SA. What is an antibiotic or an antibiotic substance? Mycologia 1947 ; 39 : 565–9. [Google Scholar]
  2. Gaynes R. The discovery of penicillin—new insights after more than 75 years of clinical use. Emerg Infect Dis 2017 ; 23 : 849–53. [Google Scholar]
  3. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol 2019 ; 51 : 72–80. [Google Scholar]
  4. Browne AJ, Chipeta MG, Haines-Woodhouse G, et al. Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study. Lancet Planet Health 2021 ; 5 : e893–e904. [Google Scholar]
  5. Gilmore MC, Cava F. Bacterial peptidoglycan recycling. Trends Microbiol 2025 ; 33 : 340–53. [Google Scholar]
  6. El-Araby AM, Fisher JF, Mobashery S. Bacterial peptidoglycan as a living polymer. Curr Opin Chem Biol 2025 ; 84 : 102562. [Google Scholar]
  7. Massova I, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and β-lactamases. Antimicrob Agents Chemother 1998 ; 42 : 1–17. [Google Scholar]
  8. Williams JD. Classification of cephalosporins. Drugs 1987 ; 34 Suppl 2 : 15–22. [Google Scholar]
  9. Bush K, Bradford PA. β-lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med 2016 ; 6 : a025247. [Google Scholar]
  10. McCreary EK, Heil EL, Tamma PD. New perspectives on antimicrobial agents: cefiderocol. Antimicrob Agents Chemother 2021 ; 65 : e0217120. [Google Scholar]
  11. Yahav D, Giske CG, Grāmatniece A, et al. New β-lactam–β-lactamase inhibitor combinations. Clin Microbiol Rev 2020 ; 34 : e00115–20. [Google Scholar]
  12. Georgopapadakou N, Hammarström S, Strominger JL. Isolation of the penicillin-binding peptide from D-alanine carboxypeptidase of Bacillus subtilis. Proc Natl Acad Sci USA 1977 ; 74 : 1009–12. [Google Scholar]
  13. Curtis NA, Orr D, Ross GW, et al. Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity. Antimicrob Agents Chemother 1979 ; 16 : 533–9. [Google Scholar]
  14. Fernandes R, Amador P, Prudêncio C. β-Lactams: chemical structure, mode of action and mechanisms of resistance. Reviews and Research in Medical Microbiology 2013 ; 24 : 7. [Google Scholar]
  15. Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989 ; 8 : 943–50. [Google Scholar]
  16. Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005 ; 55 Suppl 2 : ii15–20. [Google Scholar]
  17. Kang H-K, Park Y. Glycopeptide antibiotics: structure and mechanisms of action. J Bacteriol Virol 2015 ; 45 : 67. [Google Scholar]
  18. Boulekbache A, Maldonado F, Kavafian R, et al. Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis. J Antimicrob Chemother 2024 ; 79 : 712–21. [Google Scholar]
  19. Hendlin D, Stapley EO, Jackson M, et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 1969 ; 166 : 122–3. [CrossRef] [PubMed] [Google Scholar]
  20. Kahan FM, Kahan JS, Cassidy PJ, et al. The mechanism of action of fosfomycin (phosphonomycin). Ann NY Acad Sci 1974 ; 235 : 364–86. [Google Scholar]
  21. Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev 2016 ; 29 : 321–47. [Google Scholar]
  22. Stansly PG, Schlosser ME. Studies on polymyxin: isolation and identification of bacillus polymyxa and differentiation of polymyxin from certain known antibiotics. J Bacteriol 1947 ; 54 : 549–56. [Google Scholar]
  23. Landman D, Georgescu C, Martin DA, et al. Polymyxins revisited. Clin Microbiol Rev 2008 ; 21 : 449–465. [Google Scholar]
  24. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005 ; 40 : 1333–41. [Google Scholar]
  25. Barbier F, Wolff M. Pseudomonas aeruginosa multirésistant : vers une impasse thérapeutique ?. Med Sci (Paris) 2010 ; 26 : 960–8. [Google Scholar]
  26. Eisenstein BI, Oleson FB Jr, Baltz RH. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis 2010 ; 50 : S10–5. [Google Scholar]
  27. Miller WR, Bayer AS, Arias CA. Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci. Cold Spring Harb Perspect Med 2016 ; 6 : a026997. [Google Scholar]
  28. Boulekbache A, Maldonado F, Kavafian R, et al. Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis. J Antimicrob Chemother 2024 ; 79 : 712–21. [Google Scholar]
  29. Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother 2003 ; 51 Suppl 1 : 13–20. [Google Scholar]
  30. Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol 2015 ; 10 : 1111–23. [Google Scholar]
  31. Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med 2016 ; 6 : a025320. [Google Scholar]
  32. Hardie KR, Fenn SJ. JMM profile: rifampicin: a broad-spectrum antibiotic. J Med Microbiol 2022 ; 71. [Google Scholar]
  33. Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 2001 ; 104 : 901–12. [Google Scholar]
  34. Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure–cytotoxicity and resistance mechanisms. Journal of Antimicrobial Chemotherapy 2018 ; 73 : 265–79. [Google Scholar]
  35. Hernández Ceruelos A, Romero-Quezada LC, Ruvalcaba Ledezma JC, et al. Therapeutic uses of metronidazole and its side effects: an update. Eur Rev Med Pharmacol Sci 2019 ; 23 : 397–401. [Google Scholar]
  36. Krause KM, Serio AW, Kane TR, et al. Aminoglycosides: an overview. Cold Spring Harbor Perspectives in Medicine 2016 ; 6 : a027029. [Google Scholar]
  37. Kotra LP, Haddad J, Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 2000 ; 44 : 3249–56. [CrossRef] [PubMed] [Google Scholar]
  38. Grossman TH. Tetracycline antibiotics and resistance. Cold Spring Harb Perspect Med 2016 ; 6 : a025387. [Google Scholar]
  39. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001 ; 65 : 232–60. [CrossRef] [PubMed] [Google Scholar]
  40. Kunz Coyne AJ, Alosaimy S, Lucas K, et al. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr 2024 ; 12 : e0235123. [Google Scholar]
  41. Schwarz S, Shen J, Kadlec K, et al. Lincosamides, streptogramins, phenicols, and pleuromutilins: mode of action and mechanisms of resistance. Cold Spring Harb Perspect Med 2016 ; 6 : a027037. [Google Scholar]
  42. Vázquez-Laslop N, Mankin AS. How macrolide antibiotics work. Trends Biochem Sci 2018 ; 43 : 668–84. [Google Scholar]
  43. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 2003 ; 330 : 1005–14. [Google Scholar]
  44. Burdette SD, Trotman R. Tedizolid: the first once-daily oxazolidinone class antibiotic. Clin Infect Dis 2015 ; 61 : 1315–21. [Google Scholar]
  45. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann NY Acad Sci 2011 ; 1241 : 48–70. [Google Scholar]
  46. Wilson DN, Schluenzen F, Harms JM, et al. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA 2008 ; 105 : 13339–44. [Google Scholar]
  47. Balbi HJ. Chloramphenicol: a review. Pediatr Rev 2004 ; 25 : 284–8. [Google Scholar]
  48. Fernandes P. Fusidic Acid: A bacterial elongation factor inhibitor for the oral treatment of acute and chronic staphylococcal infections. Cold Spring Harb Perspect Med 2016 ; 6 : a025437. [Google Scholar]
  49. Capasso C, Supuran CT. Sulfa and trimethoprim-like drugs - antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors. J Enzyme Inhib Med Chem 2014 ; 29 : 379–87. [Google Scholar]
  50. Masters PA, O’Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003 ; 163 : 402–10. [Google Scholar]
  51. Sanders P. Résistance antimicrobienne des bactéries zoonotiques : stratégies actuelles en médecine vétérinaire. Med Sci (Paris) 2010 ; 26 : 930–5. [Google Scholar]
  52. Butler MS, Henderson IR, Capon RJ, et al. Antibiotics in the clinical pipeline as of December 2022. J Antibiot (Tokyo) 2023 ; 76 : 431–73. [CrossRef] [PubMed] [Google Scholar]
  53. Lacotte Y, Jouvin-Marche E, Ploy M-C. EU-JAMRAI - L’Europe s’engage à apporter une réponse coordonnée et à adopter une approche « une seule santé » pour lutter contre la résistance aux antibiotiques. Med Sci (Paris) 2025 ; 41 : 211–2. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.